KRAS G12C inhibitors, including sotorasib and adagrasib, have revolutionized the treatment landscape for certain malignancies, particularly non–small cell lung cancer (NSCLC) and colorectal cancer (CRC), where they have received FDA approval. This evidence concerns the gene KRAS and non-small cell lung carcinoma.